Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin receptor antagonists--an overview.

Falguni Dasgupta1, Ashis K Mukherjee, N Gangadhar

  • 1BioMarin Pharmaceutical Inc., 11 Pimentel Ct., Novato, CA 94949, USA. fdcarbo@hotmail.com

Current Medicinal Chemistry
|April 12, 2002
PubMed
Summary

Endothelin (ET) receptor antagonists are being developed as novel therapeutics for cardiovascular diseases (CVDs). These compounds offer potential treatments for conditions like hypertension and heart failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Function of miRNAs in Conferring Neuroprotection through a Tailored Peptide Derived from Snake Venom Nerve Growth Factor in Response to Paraquat-Induced Toxicity in <i>Caenorhabditis elegans</i>.

ACS omega·2026
Same author

The antidiabetic potential of Leuconostoc mesenteroides strain SB1075 fermented soy yoghurt: Insights from mouse intestinal transcriptomics and metabolite analyses.

Food research international (Ottawa, Ont.)·2026
Same author

Indian lone commercial antivenom against Indian red scorpion venom demonstrates limited immunorecognition and partial neutralisation of enzymatic, pharmacological, and some toxic effects of Heterometrus bengalensis (Indian black scorpion) venom proteins in vitro and in vivo.

International journal of biological macromolecules·2026
Same author

Inadequate immunorecognition and ineffective paraspecific neutralisation of lethality and toxicity of Trimeresurus erythrurus venom by Indian polyvalent antivenom compared to Trimeresurus popeiorum venom.

Toxicon : official journal of the International Society on Toxinology·2026
Same author

A commercial insecticide-induced neurotoxicity and snake venom nerve growth factor-inspired peptides-mediated neuroprotection in Caenorhabditis elegans: Mechanistic, safety, and pharmacokinetic (in vivo imaging) evaluation of peptides.

Toxicon : official journal of the International Society on Toxinology·2026
Same author

Clinical Case Reports on Black Krait (Bungarus niger/lividus) Neurotoxic Snakebites in Assam, Northeast India.

The American journal of tropical medicine and hygiene·2026

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Cardiovascular Medicine

Background:

  • Endothelin (ET) is implicated in various diseases, particularly cardiovascular diseases (CVDs).
  • Medicinal chemists are actively seeking novel therapeutics targeting the ET pathway.
  • Understanding ET's role is crucial for developing effective treatments.

Purpose of the Study:

  • To review and classify Endothelin receptor antagonists.
  • To highlight structure-activity relationship studies and compound library screenings.
  • To present the current landscape of ET antagonist research.

Main Methods:

  • Structure-activity relationship (SAR) studies of ET antagonists.
  • Screening of compound libraries for ET receptor antagonists.

Related Experiment Videos

  • Review of emerging small molecules targeting the ET pathway.

    • Main Results:

    • A diverse range of small molecule ET receptor antagonists have been identified.
    • Ongoing investigations reveal new opportunities in ET antagonist research.
    • Several compounds are currently in clinical trials for various pathologies.

    Conclusions:

    • ET receptor antagonists represent a promising therapeutic strategy for cardiovascular diseases.
    • The development of these antagonists aids in understanding ET's physiological roles.
    • Clinical evaluation is underway for conditions such as essential hypertension and chronic heart failure.